文献速递妇科

后路经阴道网片与自体组织修补治疗盆腔器官脱垂的多中心前瞻性研究:36个月结局

A Multicenter Prospective Study of Posterior Transvaginal Mesh Compared to Native Tissue Repair for Pelvic Organ Prolapse: 36 Month Outcomes.
PubMed 文献 · J Minim Invasive Gynecol · 2025-06-26

这项多中心前瞻性队列研究比较Restorelle® DirectFix经阴道网片与自体组织修补(NTR)治疗盆腔器官脱垂(POP)的疗效与安全性,报告后壁及顶端腔室队列12个月和36个月随访数据。共纳入239例女性(网片组163例,NTR组76例),术后随访至36个月。结果显示两组脱垂复发率及严重不良事件相近,网片暴露率为3.5%。

要点

  • 12个月时后壁网片组脱垂复发率为11.7%,NTR组为13.2%。
  • 36个月时两组复发率分别升至18%和27%。
  • 两组生活质量评分均显著改善,手术满意度相似,严重不良事件低且相近。

核心结论

  • Restorelle® DirectFix后路网片治疗后壁及顶端腔室脱垂在36个月内的疗效与安全性与NTR相当。

研究设计与样本

  • 多中心前瞻性队列研究,在美国、加拿大、荷兰、比利时、法国和澳大利亚的38家医院开展。
  • 2014年9月至2018年8月纳入239例女性,其中网片组163例、NTR组76例。
  • 术后2、6、12、18、24和36个月进行随访。

主要发现

  • 12个月时后壁网片组脱垂复发率为11.7%,NTR组为13.2%。
  • 36个月时后壁网片组脱垂复发率为18%,NTR组为27%。
  • 两组生活质量评分均显著改善,手术满意度水平相似。
  • 严重不良事件发生率低且两组相当。
  • 网片组网片暴露发生率为3.5%,无严重并发症。

关键数值与推荐

  • 主要疗效终点为12个月时目标腔室的脱垂复发。
  • 次要结局包括36个月脱垂复发、严重不良事件、生活质量改善和手术满意度。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY OBJECTIVE: This multicenter, prospective cohort study aimed to evaluate the efficacy and safety of Restorelle® DirectFix transvaginal mesh compared to native tissue repair (NTR) in pelvic organ prolapse (POP). This manuscript reports on the 12- and 36-months follow-up data in the posterior and apical compartment cohort of this study. DESIGN: Participants, stratified into mesh (163 women) and NTR (76 women) groups, were seen at 2, 6, 12, 18, 24, and 36 months postsurgery. SETTING: The study was conducted at 38 hospitals in the United States, Canada, the Netherlands, Belgium, France, and Australia. PATIENTS: A total of 239 women were enrolled in the posterior arm of this FDA-mandated Restorelle DirectFix 522 study postmarket surveillance study between September 2014 and August 2018. INTERVENTIONS: Restorelle® DirectFix transvaginal mesh compared to native tissue repair (NTR) MEASUREMENTS: The primary efficacy endpoint was prolapse recurrence in the target compartment at 12 months, with secondary outcomes assessing prolapse recurrence at 36 months, serious adverse events, quality of life improvements, and surgical satisfaction based on various validated instruments. MAIN RESULTS: At 12 months, and despite notable differences in baseline characteristics with a poorer prognostic population in the posterior mesh-arm, the prolapse recurrence rate was 11.7% in the posterior mesh-arm and 13.2% in the NTR-arm, increasing to 18% and 27% at 36 months, respectively. Quality of life scores showed significant improvement in both groups, with similar levels of surgical satisfaction. Serious adverse events were low and comparable between the groups. Mesh exposure occurred in 3.5% of the mesh group without any serious complications. CONCLUSION: Restorelle® DirectFix Posterior mesh demonstrated comparable efficacy and safety to NTR for treating posterior and apical compartment prolapse over a 36-month period. Clinical Trial Identification Number: NCT02162615. https://clinicaltrials.gov/study/NCT02162615. Registration date June 11, 2014.

来源:J Minim Invasive Gynecol,查看原文。版权归原作者所有。

引用

  1. Sokol ER, Cosson M, Harris-Hicks JE, et al. A Multicenter Prospective Study of Posterior Transvaginal Mesh Compared to Native Tissue Repair for Pelvic Organ Prolapse: 36 Month Outcomes. J Minim Invasive Gynecol. 2025. PMID: 40581283. doi:10.1016/j.jmig.2025.06.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。